Food, drugs, devices › Lupin Pharmaceuticals Inc.

Drug recall: Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium

FDA enforcement event 92588 · Class I · initiated 23 Jun 2023 · status Terminated · terminated 28 Jan 2025

DrugVoluntary: Firm initiated1 product recordBaltimore, MD

FDA enforcement event 92588 is a drug recall by Lupin Pharmaceuticals Inc. of Baltimore, MD, initiated 23 Jun 2023 and classified Class I, with 1 product record.

FDA defines Class I as a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. 15% of the 281 drug enforcement events initiated in 2023 carry the same class.

Status: Terminated, terminated 28 Jan 2025. Initiation: voluntary: firm initiated. Lupin Pharmaceuticals Inc. has 91 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Lupin Pharmaceuticals Inc., Baltimore, MD.

Reason for recall

"Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test"

Distribution

"USA nationwide."

Product records

Recall number	Product	Quantity	Class	Status	Report date
D-1081-2023	Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets 0.451 mg), packaged in 1 blister of 28 tablets each (NDC 68180-904-71) further packaged in a carton of 3 blisters (NDC 68180-904-73), Distributed by: Lupin Pharmaceuticals, Inc., Baltimore,…	4,179 boxes/_ cartons per box/3 pouches each/28 blister per pouch	Class I	Terminated	9 Aug 2023

Context

15%of 2023 drug events are Class I281 events that year

1product record in this eventfirm median: 1

91events on this register for the firm

Other enforcement events for Lupin Pharmaceuticals Inc.

Initiated	Product (first record)	Type	Class	Records
3 Aug 2026	Clobetasol Propionate Cream USP, 0.05%, 60 g tube, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34	Drug	Class II	1
23 Jun 2026	Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per vial, Diluent for Glucagon, 1 mL syringe	Drug	Class II	1
4 Jun 2026	prednisoLONE Acetate Ophthalmic Suspension, USP, 1%, Rx only, Sterile, a) 5 mL (NDC 70748-332-02); b) 10 mL (NDC 70748-3	Drug	Class II	1
24 Apr 2026	Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, M	Drug	Class II	1
13 Nov 2025	Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Man	Drug	Class II	1
5 Nov 2025	Sertraline Hydrochloride Tablets USP, 100 mg, 90 Tablets bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc.,	Drug	Class II	1
2 Jul 2025	Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx Only, Manufactured for: Lupin Pharmaceu	Drug	Class II	1
27 Jun 2025	clomiPRAMINE Hydrochloride Capsules USP 25 mg, 100 count bottles, 5801 Pelican Bay Boulevard, Suite 500, Naples, Florida	Drug	Class II	1
20 Jun 2025	Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals,	Drug	Class II	1
10 Apr 2025	clomiPRAMINE hydrochloride Capsules USP, 25 mg, 100-count bottle, Rx only, Manufactured For: Lupin Pharmaceuticals, Inc.	Drug	Class II	1

All 91 events for Lupin Pharmaceuticals Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test"

What does Class I mean?

FDA classifies recalls by relative degree of health hazard. Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

Where was the product distributed?

FDA's distribution pattern field reads: "USA nationwide."

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 28 Jan 2025. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.